Circulating unconventional T-cell subsets during treatment with BCR-ABL1 tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia

MeSH terms

• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / therapeutic use*
• Biomarkers
• Fusion Proteins, bcr-abl / antagonists & inhibitors*
• Humans
• Immunophenotyping
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
• Lymphocyte Count*
• Molecular Targeted Therapy
• Protein Kinase Inhibitors / administration & dosage
• Protein Kinase Inhibitors / adverse effects
• Protein Kinase Inhibitors / therapeutic use*
• T-Lymphocyte Subsets* / metabolism
• Treatment Outcome